These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current approaches to cysticidal drug therapy for neurocysticercosis. Del Brutto OH. Expert Rev Anti Infect Ther; 2020 Aug; 18(8):789-798. PubMed ID: 32331507 [Abstract] [Full Text] [Related]
7. Cysticercosis and epilepsy: a critical review. Carpio A, Escobar A, Hauser WA. Epilepsia; 1998 Oct; 39(10):1025-40. PubMed ID: 9776322 [Abstract] [Full Text] [Related]
8. Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis. Garcia HH, Lescano AG, Gonzales I, Bustos JA, Pretell EJ, Horton J, Saavedra H, Gonzalez AE, Gilman RH, Cysticercosis Working Group in Peru. Clin Infect Dis; 2016 Jun 01; 62(11):1375-9. PubMed ID: 26984901 [Abstract] [Full Text] [Related]
9. Neurocysticercosis: Clinical Characteristics and Changes from 26 Years of Experience in an University Hospital in Korea. Son HJ, Kim MJ, Jung KH, Choi S, Jung J, Chong YP, Kim SH, Lee SO, Choi SH, Kim YS, Woo JH, Jung BK, Song H, Chai JY. Korean J Parasitol; 2019 Jun 01; 57(3):265-271. PubMed ID: 31284349 [Abstract] [Full Text] [Related]
10. Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution. Garcia HH, Del Brutto OH, Cysticercosis Working Group in Peru. Epilepsy Behav; 2017 Nov 01; 76():158-162. PubMed ID: 28606690 [Abstract] [Full Text] [Related]
11. Extraparenchymal neurocysticercosis: report of five cases and review of management. Bandres JC, White AC, Samo T, Murphy EC, Harris RL. Clin Infect Dis; 1992 Nov 01; 15(5):799-811. PubMed ID: 1445979 [Abstract] [Full Text] [Related]
12. Medical and surgical treatment in neurocysticercosis a magnetic resonance study of 161 cases. Martinez HR, Rangel-Guerra R, Arredondo-Estrada JH, Marfil A, Onofre J. J Neurol Sci; 1995 May 01; 130(1):25-34. PubMed ID: 7650528 [Abstract] [Full Text] [Related]
13. Antigenic fractions from Taenia crassiceps metacestodes obtained by hydrophobicity for the immunodiagnosis of active and inactive forms of neurocysticercosis in human cerebrospinal fluid samples. da Silva GB, Nunes DS, de Sousa JEN, Gonçalves-Pires MDRF, Levenhagen MA, Costa-Cruz JM. Parasitol Int; 2017 Apr 01; 66(2):134-138. PubMed ID: 28012796 [Abstract] [Full Text] [Related]
15. Monitoring treatment of Taenia solium- neurocysticercosis by detection of circulating antigens: a case report. Rodríguez-Hidalgo R, Carpio A, Van den Enden E, Benítez-Ortiz W. BMC Neurol; 2019 Apr 03; 19(1):52. PubMed ID: 30943908 [Abstract] [Full Text] [Related]
17. Medical management of neurocysticercosis. Takayanagui OM, Odashima NS, Bonato PS, Lima JE, Lanchote VL. Expert Opin Pharmacother; 2011 Dec 03; 12(18):2845-56. PubMed ID: 22082143 [Abstract] [Full Text] [Related]
18. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. Proaño JV, Madrazo I, Avelar F, López-Félix B, Díaz G, Grijalva I. N Engl J Med; 2001 Sep 20; 345(12):879-85. PubMed ID: 11565520 [Abstract] [Full Text] [Related]